Event-Driven Immunoprofiling Predicts Return of Disease Activity in Alemtuzumab-Treated Multiple Sclerosis

Overview of attention for article published in Frontiers in immunology, January 2020

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (84th percentile)
High Attention Score compared to outputs of the same age and source (87th percentile)

Mentioned by

blogs: 1 blog

twitter: 6 X users

Citations

dimensions_citation: 20 Dimensions

Readers on

mendeley: 29 Mendeley

Summary Blogs X Dimensions citations

So far, Altmetric has seen 6 X posts from 6 X users, with an upper bound of 7,014 followers.

Event-Driven Immunoprofiling Predicts Return of Disease Activity in Alemtuzumab-Treated Multiple Sclerosis. https://t.co/RclCObRfqm

22 Feb 2020

Reply Repost Favourite

New article: Event-Driven Immunoprofiling Predicts Return of Disease Activity in Alemtuzumab-Treated Multiple Sclerosis. https://t.co/LTMxAjBJdr #MS #multiplesclerosis #neurology

22 Feb 2020

Reply Repost Favourite

RT @DraganaObrado20: 16 #alemtuzumab treated #MS pts, 9 complete responders, 85 months follow-up. Th1 and Th17 cells markedly decreased, re…

11 Feb 2020

Reply Repost Favourite

16 #alemtuzumab treated #MS pts, 9 complete responders, 85 months follow-up. Th1 and Th17 cells markedly decreased, remained below baseline levels notably in complete-responders. Event-driven immunoprofiling showed Th1 and Th17 cells increase 6 months befo

11 Feb 2020

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 2 additional X posts.